Stock Research: JW Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

JW Pharmaceutical

KOSE:A001060 KR7001060003
67
  • Value
    30
  • Growth
    34
  • Safety
    Safety
    76
  • Combined
    43
  • Sentiment
    92
  • 360° View
    360° View
    67
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

JW Pharmaceutical Corp develops and manufactures pharmaceuticals. The company operates in the pharmaceutical industry, producing drugs for various treatments. Based in Korea, the company also researches anticancer drugs. In the last fiscal year, the company had a market cap of $416 million, profits of $219 million, and revenue of $487 million. The number of employees is unavailable.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 67 (better than 67% compared with alternatives), overall professional sentiment and financial characteristics for the stock JW Pharmaceutical are above average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for JW Pharmaceutical. The consolidated Value Rank has an attractive rank of 76, which means that the share price of JW Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 76% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 92, which means that professional investors are more optimistic about the stock than for 92% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 34, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 30, meaning the company has a riskier financing structure than 70 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
KOSPI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
76 68 42 53
Growth
34 55 59 23
Safety
Safety
30 52 12 16
Sentiment
92 74 61 84
360° View
360° View
67 78 34 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
95 100 91 71
Opinions Change
50 33 29 50
Pro Holdings
n/a 70 64 65
Market Pulse
1 1 n/a n/a
Sentiment
92 74 61 84
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
76 68 42 53
Growth
34 55 59 23
Safety Safety
30 52 12 16
Combined
43 72 23 8
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
97 90 58 81
Price vs. Earnings (P/E)
88 87 68 92
Price vs. Book (P/B)
30 29 25 30
Dividend Yield
52 44 37 40
Value
76 68 42 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
57 64 63 53
Profit Growth
27 42 45 23
Capital Growth
63 100 3 72
Stock Returns
18 10 99 17
Growth
34 55 59 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
33 28 3 6
Refinancing
44 34 25 53
Liquidity
32 80 26 8
Safety Safety
30 52 12 16

Similar Stocks

Discover high‑ranked alternatives to JW Pharmaceutical and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

AMOREPACIFIC

KOSE:A002790
Country: South Korea
Industry: Personal Products
Size: Medium
Full Stock Analysis

NH Investment & Securities

KOSE:A005940
Country: South Korea
Industry: Investment Banking & Brokerage
Size: Medium
Full Stock Analysis

Hisamitsu Pharmaceutical

TSE:4530
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.